GeneDx Holdings Warrant
WGSWW
WGSWW was delisted on the 21st of July, 2026.
20 hedge funds and large institutions have $50.8K invested in GeneDx Holdings Warrant in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0.89% less ownership
Funds ownership: 1.54% → 0.65% (-0.89%)
5% less funds holding
Funds holding: 21 → 20 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
92% less capital invested
Capital invested by funds: $641K → $50.8K (-$591K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$83 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Difesa Capital Management
New York
|
-$14.2K |
| 2 |
Jane Street
New York
|
-$286 |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$86 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$68 |
| 5 |
GS
Gagnon Securities
New York
|
-$3 |
WGSWW Hedge Fund Activity: Q2 2023 in Review
20 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in GeneDx Holdings Warrant (WGSWW) for Q2 2023, worth a combined $50.8K — down 92% from $641K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of WGSWW and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $83. The largest seller was Difesa Capital Management, exiting entirely with an estimated $14.2K sold.
- 20 institutional investors held GeneDx Holdings Warrant (WGSWW) as of Q2 2023, down from 21 in Q1 2023.
- Funds reported $50.8K of GeneDx Holdings Warrant stock for Q2 2023, down 92% quarter-over-quarter.
- 1 fund opened new GeneDx Holdings Warrant positions in Q2 2023 and 2 closed out, a net change of -1 holder.
- The largest GeneDx Holdings Warrant buyer in Q2 2023 was Morgan Stanley, an estimated $83 added.
- The largest GeneDx Holdings Warrant seller in Q2 2023 was Difesa Capital Management, an estimated $14.2K sold.
Based on aggregated 13F filings for Q2 2023.